Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now early-phase tilt small index

Urologic Diseases: early-phase trial registry

6 of 12 indexed Urologic Diseases trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,429 of 28,707 conditions by registered trial count.

12 US clinical trials · 6 currently recruiting · #1,429 of 28,707 conditions by registered trial count

Urologic Diseases: 12 US clinical trials tracked, 6 recruiting.

Urologic Diseases is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Northwestern University, running 2 of these trials.

Enrollment posture brief

Registry condition urologic-diseases

OPEN 6 | RECR 50% | LATE 1 | EARLY 3 | RANK #1429 | SPON 2

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Urologic Diseases (this)50%Acute Myeloid Leukemia in Re41.7%Adenocarcinoma of the Rectum41.7%Adherence, Patient16.7%Accelerated Phase Chronic My0%
Open-enrollment share among volume-matched conditions near Urologic Diseases

Urologic Diseases lists 6 open slots (50% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Urologic Diseases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Urologic Diseases is recruiting above its size-band peers.

    6 of 12 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Urologic Diseases research.

    Northwestern University accounts for 2 of 12 trials (16.7%). 11 distinct sponsors appear on at least one study for this condition label.

  3. Most Urologic Diseases trials plan to enrol fewer than 100 people.

    Median target enrolment is 75 among the 12 trials that report a genuine target (sentinel values excluded). 8 of those (66.7%) plan for fewer than 100 participants.

  4. Urologic Diseases research is mostly interventional.

    10 interventional and 2 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 21Phase 31

Open and recent trials

12 total, page 1 of 1

RECRUITING NA 300 participants

Laser Outcomes Associated With (Holmium Laser Enucleation of the Prostate) HoLEP Procedures

Northwestern University

NCT06531473

RECRUITING 180 participants

Development of a New Canadian Endourology Group Stent Symptom Score

Centre hospitalier de l'Université de Montréal (CHUM)

NCT04909541

RECRUITING Phase 2 80 participants

Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms

Northwestern University

NCT05878951

RECRUITING NA 60 participants

Patient Satisfaction of Virtual vs In-Person Workup and Treatment of Lower Urinary Tract Symptoms.

Indiana University

NCT05508165

RECRUITING NA 28 participants

Trial for Reliability of Urodynamics SysTem

Bright Uro

NCT05694793

RECRUITING Phase 1 10 participants

Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures

Wake Forest University Health Sciences

NCT03258658

ACTIVE NOT RECRUITING NA 208 participants

INTIBIA Pivotal Study

Coloplast A/S

NCT05250908

ACTIVE NOT RECRUITING Phase 3 75 participants

Long Term Extension Study in Patients With Primary Hyperoxaluria

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

NCT04042402

COMPLETED NA 330 participants

Effects of a Cranberry Beverage on Women With Recent History of Urinary Tract Infections

Ocean Spray Cranberries

NCT01776021

COMPLETED 32 participants

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FAST PV and mGFR Technology™

FAST BioMedical

NCT03095391

COMPLETED Phase 1 15 participants

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

Lipac Oncology

NCT03081858

COMPLETED NA 9 participants

Percutaneous Externally-Assembled Laparoscopic Urologic Surgery

Loma Linda University

NCT02811601

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 1
Phase 3 1

Named interventions

Most-linked intervention names on Urologic Diseases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

TSD-001 Drug
1 trials
Iohexol Device
1 trials
VFI Device
1 trials
PEAL surgery Procedure
1 trials
placebo beverage Other
1 trials
cranberry juice Other
1 trials
INTIBIA Non-Therapeutic Device
1 trials
INTIBIA Therapeutic Device
1 trials

US sites by state

Facility locations filed on Urologic Diseases trials. A trial with sites in several states counts in each.

California 8 trials
Ohio 4 trials
Texas 3 trials
Illinois 3 trials
South Carolina 2 trials
North Carolina 2 trials
Minnesota 2 trials
Massachusetts 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Urologic Diseases page

12 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Urologic Diseases condition card totals 12 registered trials; most-linked intervention TSD-001; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.